Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis

Tuberculosis

Volumn 87, Issue 6, 2007, Pages 551-556

  Cho, Hyun Jung ^a   Koh, Won Jung ^a   Ryu, Yon Ju ^a   Ki, Chang Seok ^a   Nam, Myung Hyun ^b   Kim, Jong Won ^a   Lee, Soo Youn ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

CYP2E1; Hepatotoxicity; Isoniazid; Korean; NAT2

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450 2E1; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CYP2E1 GENE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KOREA; LIVER INJURY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAT2 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TOXIC HEPATITIS;

ADULT; AGED; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP2E1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 35348922264     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2007.05.012     Document Type: Article

References (38)

1. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 333 (1995) 1118-1127
2. Pande J.N., Singh S.P., Khilnani G.C., Khilnani S., and Tandon R.K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51 (1996) 132-136
3. Wong W.M., Wu P.C., Yuen M.F., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31 (2000) 201-206
4. Huang Y.S., Chern H.D., Su W.J., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35 (2002) 883-889
5. Black M., Mitchell J.R., Zimmerman H.J., Ishak K.G., and Epler G.R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69 (1975) 289-302
6. Mitchell J.R., Zimmerman H.J., Ishak K.G., et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84 (1976) 181-192
7. Byrd R.B., Horn B.R., Solomon D.A., and Griggs G.A. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA 241 (1979) 1239-1241
8. Dickinson D.S., Bailey W.C., Hirschowitz B.I., Soong S.J., Eidus L., and Hodgkin M.M. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 3 (1981) 271-279
9. Hwang S.J., Wu J.C., Lee C.N., et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 12 (1997) 87-91
10. Yamamoto T., Suou T., and Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 6 (1986) 295-298
11. Farrell G.C. Drug-induced acute hepatitis. In: Farrell G.C. (Ed). Drug-induced liver disease (1994), Churchill Livingstone, Edibburgh 247-299
12. Ryan D.E., Ramanathan L., Iida S., et al. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Biol Chem 260 (1985) 6385-6393
13. Mitchell J.R., Thorgeirsson U.P., Black M., et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 18 (1975) 70-79
14. Lauterburg B.H., Smith C.V., Todd E.L., and Mitchell J.R. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 235 (1985) 566-570
15. Sarma G.R., Immanuel C., Kailasam S., Narayana A.S., and Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 133 (1986) 1072-1075
16. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11 (1990) 272-276
17. Gronhagen-Riska C., Hellstrom P.E., and Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 118 (1978) 461-466
18. Gurumurthy P., Krishnamurthy M.S., Nazareth O., et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 129 (1984) 58-61
19. Parthasarathy R., Sarma G.R., Janardhanam B., et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 67 (1986) 99-108
20. Hiratsuka M., Kishikawa Y., Takekuma Y., et al. Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 17 (2002) 357-362
21. Ohno M., Yamaguchi I., Yamamoto I., et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4 (2000) 256-261
22. Schimizu Y., Dobashi K., Mita Y., et al. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis 86 (2006) 374-381
23. Chen B., Li J.H., Xu Y.M., Wang J., and Cao X.M. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients. Clin Chim Acta 365 (2006) 104-108
24. Lee S.Y., Lee K.A., Ki C.S., et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem 48 (2002) 775-777
25. Lucas D., Menez C., Girre C., et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 5 (1995) 298-304
26. Powell H., Kitteringham N.R., Pirmohamed M., Smith D.A., and Park B.K. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 8 (1998) 411-421
27. Huang Y.S., Chern H.D., Su W.J., et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37 (2003) 924-930
28. Vuilleumier N., Rossier M.F., Chiappe A., et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 62 (2006) 423-429
29. Yu M.W., Gladek-Yarborough A., Chiamprasert S., Santella R.M., Liaw Y.F., and Chen C.J. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 109 (1995) 1266-1273
30. McCarver D.G., Byun R., Hines R.N., Hichme M., and Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 152 (1998) 276-281
31. Hu Y., Hakkola J., Oscarson M., and Ingelman-Sundberg M. Structural and functional characterization of the 5′-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 263 (1999) 286-293
32. Fritsche E., Pittman G.S., and Bell D.A. Localization, sequence analysis, and ethnic distribution of a 96-bp insertion in the promoter of the human CYP2E1 gene. Mutat Res 432 (2000) 1-5
33. Itoga S., Harada S., and Nomura F. Polymorphism of the 5′-flanking region of the CYP2E1 gene: an association study with alcoholism. Alcohol Clin Exp Res 25 (2001) 11S-15S
34. Howard L.A., Ahluwalia J.S., Lin S.K., Sellers E.M., and Tyndale R.F. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics 13 (2003) 321-328
35. Maria V.A.J., and Victorino R.M.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 26 (1997) 664-669
36. Aithal G.P., Rawlins M.D., and Day C.P. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 33 (2003) 942-952
37. Branch R.A., Adedoyin A., Frye R.F., Wilson J.W., and Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampicin. Clin Pharmacol Ther 68 (2000) 401-411
38. Zand R., Nelson S.D., Slattery J.T., et al. Inhibition and induction of cytochrome P4502E1-catalysed oxidation by isoniazid in humans. Clin Pharmacol Ther 54 (1993) 142-149